Magnesium trisilicate compound tablets
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Aluminium hydroxide + Magnesium trisilicate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
10 branded products available
MHRA licensed products
View all licensed products for Aluminium hydroxide + Magnesium trisilicate on the MHRA register
Magnesium trisilicate compound tablets
Magnesium trisilicate compound tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · 1988–2025
Showing the 50 most relevant studies, sorted by most relevant.
Krewski D, Yokel RA, Nieboer E, et al.
2007
- Aluminum Hydroxide
- Aluminum Oxide
- Aluminum
S. Saha, Sayantan Ray, R. Acharya, et al.
Applied Clay Science, 2017
L. Haurie, A. I. Fernández, J. Velasco, et al.
Polymer Degradation and Stability, 2007
N. LeBozec, D. Thierry, D. Persson, et al.
Surface and Coatings Technology, 2019
Guowei Li, Jiawei Huang, Jian Zhou, et al.
Journal of Materials Chemistry A, 2024
Guerrero-Romero F, Micke O, Simental-Mendía LE, et al.
2023
A large amount of published research points to the interesting concept (hypothesis) that magnesium (Mg) status may have relevance for the outcome of COVID-19 and that Mg could be protective during the COVID disease course. As an essential element, Mg plays basic biochemical, cellular, and physiological roles required for cardiovascular, immunological, respiratory, and neurological functions. Both low serum and dietary Mg have been associated with the severity of COVID-19 outcomes, including mortality; both are also associated with COVID-19 risk factors such as older age, obesity, type 2 diabetes, kidney disease, cardiovascular disease, hypertension, and asthma. In addition, populations with high rates of COVID-19 mortality and hospitalization tend to consume diets high in modern processed foods, which are generally low in Mg. In this review, we review the research to describe and consider the possible impact of Mg and Mg status on COVID-19 showing that (1) serum Mg between 2.19 and 2.26 mg/dL and dietary Mg intakes > 329 mg/day could be protective during the disease course and (2) inhaled Mg may improve oxygenation of hypoxic COVID-19 patients. In spite of such promise, oral Mg for COVID-19 has thus far been studied only in combination with other nutrients. Mg deficiency is involved in the occurrence and aggravation of neuropsychiatric complications of COVID-19, including memory loss, cognition, loss of taste and smell, ataxia, confusion, dizziness, and headache. Potential of zinc and/or Mg as useful for increasing drug therapy effectiveness or reducing adverse effect of anti-COVID-19 drugs is reviewed. Oral Mg trials of patients with COVID-19 are warranted.
Abstract licence: CC BY
J. Gembus, Vera Bracht, Florens Grimm, et al.
Journal of Physics D: Applied Physics, 2025
Xiaojun Ren, Tongxi Lin, Bing Sun, et al.
Advanced Science, 2025
Dan Persson, Alexander Wärnheim, N. LeBozec, et al.
Corrosion and Materials Degradation, 2025
Nurul Syafiqah Mohamad Nizam, Tengku Nuraiti Tengku Izhar, Farah Naemah Mohd Saad, et al.
E3S Web of Conferences, 2024
Natural fiber panels have gained attention as sustainable alternatives in various applications, including construction and interior design. Although these fibres are highly valued for their environmental sustainability and acoustic advantages, they are inherently flammable. These panels, when subjected to fire or high-temperature conditions, pose significant safety risks due to their flammability and potential for rapid combustion. This study evaluates the efficacy of various synthetic additives in enhancing the flame retardancy of natural fiber panels. The panels were made by mixing the natural fiber with polyester resin and additives. The experimental setup includes standard fire tests such as ASTM D635 Horizontal Burning and ASTM D3801 Vertical Burning Test. The results show that rice husk demonstrates a slower burning rate when combined with both magnesium hydroxide and aluminium hydroxide, indicating better flame retardancy. Coconut coir outperforms rice husk and sawdust for both magnesium hydroxide and aluminium hydroxide which are 655 s and 640 s respectively in terms of vertical burning. The study showed that magnesium hydroxide is a better flame retardant than aluminium hydroxide. This makes it a promising option for enhancing the fire resistance of natural fiber panels.
Abstract licence: CC BY 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.